DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1

Stéphanie Braillard, Martine Keenan, Karen J. Breese, Jacob Heppell, Michael Abbott, Rafiqul Islam, David M. Shackleford, Kasiram Katneni, Elly Crighton, Gong Chen, Rahul Patil, Given Lee, Karen L. White, Sandra Carvalho, Richard J. Wall, Giulia Chemi, Fabio Zuccotto, Silvia González, Maria Marco, Julianna DeakyneDavid Standing, Gino Brunori, Jonathan J. Lyon, Pablo Castañeda-Casado, Isabel Camino, Maria S. Martinez Martinez, Bilal Zulfiqar, Vicky M. Avery, Pim Bart Feijens, Natascha Van Pelt, An Matheeussen, Sarah Hendrickx, Louis Maes, Guy Caljon, Vanessa Yardley, Susan Wyllie, Susan A. Charman, Eric Chatelain

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science